New hope for Tough-to-Treat lung cancer: first human trial begins
NCT ID NCT06461156
Summary
This is an early-stage study testing a new oral medication called HS-10504 for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change (EGFR C797S mutation) and has worsened after previous targeted treatments. The main goals are to find a safe dose, see how the drug moves through the body, and check for any early signs that it might help control the cancer. The study will enroll about 230 participants in China.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, China
Conditions
Explore the condition pages connected to this study.